antithrombotic treatment strategies in the Netherlands in patients undergoing transcatheter aortic valve implantation (TAVI) were assessed. To that purpose, for every Dutch hospital performing TAVI (n = 14) an interventional cardiologist experienced in performing TAVI was interviewed concerning heparin, aspirin, thienopyridine and oral anticoagulation treatment in patients undergoing TAVI. It was shown that the antithrombotic policy for patients undergoing TAVI is rather variable: aspirin was prescribed in all centres, clopidogrel in 13 of the 14 centres whereby the duration of clopidogrel therapy was 3 months in over two-thirds of cases. As a standardised regimen might further reduce haemorrhagic complications, large randomised clinical trials may help to establish the most appropriate approach. This national multicentre study has been cited in, among other journals, the JAMA Journal of the American Medical Association.
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